7‐AAD

:   7‐aminoactinomycin D

ATP

:   adenosine triphosphate

B‐ALL

:   B‐cell acute lymphoblastic leukemia

BID

:   bis in die

BiscFv

:   bivalent single‐chain variable fragment

CLL

:   chronic lymphatic lymphoma

CSC

:   China Scholarship Council

DT

:   diphtheria toxin

G~4~S

:   four glycine residues and one serine residue

His

:   histidine

IACUC

:   Institutional Animal Care and Use Committee

IC~50~

:   half maximal inhibitory concentration

IP

:   intraperitoneal injection

IV

:   intravenous injection

kDa

:   kilodalton

KD

:   dissociation constant

mAb

:   monoclonal antibody

MFI

:   mean fluorescence intensity

MGH

:   Massachusetts General Hospital

NHL

:   non‐Hodgkin\'s B‐cell lymphoma

Ni

:   nickel

nM

:   nanomolar

NOD/SCID

:   nonobese diabetic/severe combined immunodeficiency

*NSG*

:   NOD/SCID IL‐2 receptor γ^−/−^

PBMC

:   peripheral blood mononuclear cell

PE

:   phycoerythrin

SA

:   streptavidin

scFv

:   single‐chain variable fragment

SDS/PAGE

:   sodium dodecyl sulfate polyacrylamide gel electrophoresis

SD

:   standard deviation

VH

:   heavy chain variable domain

VL

:   light chain variable domain

1. Introduction {#mol212056-sec-0001}
===============

CD19 is a 95‐kDa transmembrane glycoprotein which is widely expressed on both normal and malignant B cells including chronic lymphatic lymphoma, non‐Hodgkin\'s B‐cell lymphoma, and B‐cell acute lymphoblastic leukemia (Turtle *et al*., [2016](#mol212056-bib-0010){ref-type="ref"}; Vallera *et al*., [2005](#mol212056-bib-0011){ref-type="ref"}). CD19 is known as a promising immunotherapy target. Anti‐human CD19 mAb drugs are already in the clinic or in clinical trials (Wang *et al*., [2012](#mol212056-bib-0013){ref-type="ref"}). However, effective antibody treatment requires the contributions of host effector mechanisms such as complement and NK cells. In contrast, immunotoxins are able to eliminate target cells even when host effector mechanisms are compromised due to chemotherapeutic agents or malnutrition. Some chemical‐conjugated anti‐human CD19 immunotoxins are already in clinical trial (Wang *et al*., [2012](#mol212056-bib-0013){ref-type="ref"}). However, these have varied degree of effectiveness and production difficulties (Vallera *et al*., [2005](#mol212056-bib-0011){ref-type="ref"}; Wayne *et al*., [2014](#mol212056-bib-0015){ref-type="ref"}). CD22‐CD19‐bispecific recombinant immunotoxin is in clinical trials (Bachanova *et al*., [2015](#mol212056-bib-0001){ref-type="ref"}; Vallera *et al*., [2005](#mol212056-bib-0011){ref-type="ref"}). However, its efficacy is dependent on target cells expressing CD22 and CD19 simultaneously. Previous attempts to produce a CD19‐specific recombinant immunotoxin have been unsuccessful (Du *et al*., [2008](#mol212056-bib-0002){ref-type="ref"}). We hypothesize that this was due to a suboptimal expression system. In this study, we developed a recombinant anti‐human CD19 immunotoxin using unique diphtheria toxin‐resistant yeast *Pichia Pastoris* expression system. The *in vitro* binding affinity and efficacy of the CD19 immunotoxin were assessed using human CD19^+^ mantle cell lymphoma cell line JeKo‐1. The *in vivo* efficacy of the CD19 immunotoxin was characterized using human CD19^+^ tumor‐bearing *NSG* mouse model.

2. Materials and methods {#mol212056-sec-0002}
========================

2.1. Cell lines and antibodies {#mol212056-sec-0003}
------------------------------

Human CD19^+^ mantle cell lymphoma cell line JeKo‐1 (cat\# CRL‐3006) and human CD19^−^ cell line CCRF‐CEM (cat\# CCL‐119) were purchased from ATCC (Manassas, VA, USA). Human CD19^−^ cell line M14 and MD‐MBA‐231 were generously provided by Soldano Ferrone (Massachusetts General Hospital). mAbs used in this study are listed in Table [1](#mol212056-tbl-0001){ref-type="table-wrap"}.

###### 

Antibodies used in this study

  Antibody Name                      Clone\#   Source      Cat\#
  ---------------------------------- --------- ----------- ----------
  PE‐mouse anti‐human CD19           FMC63     Millipore   MAB1794H
  APC‐mouse anti‐human CD4           L200      BD          551980
  FITC‐mouse anti‐human CD3Ɛ         SP‐34‐2   BD          556611
  PE‐mouse anti‐human CD3Ɛ           SP‐34‐2   BD          556612
  PE‐mouse anti‐human CD19           HIB19     BioLegend   302208
  APC‐mouse anti‐human CD8           RPA‐T8    BioLegend   301014
  FITC‐anti‐human CD14               M5E2      BioLegend   301803
  PE‐mouse anti‐human CD16           3G8       BioLegend   302008
  PE‐mouse anti‐human CD194 (CCR4)   L291H4    BioLegend   359412
  PE‐streptavidin                              BioLegend   405204
  FITC‐Annexin V                               BioLegend   640906
  7‐Aminoactinomycin (7‐AAD)                   Sigma       A9400

John Wiley & Sons, Ltd

2.2. DNA construction {#mol212056-sec-0004}
---------------------

As shown in Fig. [1](#mol212056-fig-0001){ref-type="fig"}, anti‐human CD19 immunotoxins were constructed using DT390 (Woo *et al*., [2002](#mol212056-bib-0017){ref-type="ref"}) and the codon‐optimized scFv (FMC63) nucleotide sequences (Figure 2, Nicholson *et al*., [1997](#mol212056-bib-0006){ref-type="ref"}). A strategy previously used to generate the anti‐human CCR4 immunotoxin (Wang *et al*., [2015](#mol212056-bib-0014){ref-type="ref"}) was applied to construct the anti‐human CD19 immunotoxins. DT390 and scFv (FMC63) or bi‐scFv (FMC63) are connected by a G~4~S (four glycines and one serine residue) linker. The two scFv (FMC63) of the bivalent immunotoxin are joined by (G~4~S)~3~ linker. Six histidines (6x His tag) were added to the C terminus of each construct to facilitate protein purification. To construct DT390‐scFv (FMC63), the codon‐optimized scFv (FMC63) was synthesized by GenScript and cloned into pwPICZalpha‐DT390 (Wang *et al*., [2011](#mol212056-bib-0012){ref-type="ref"}, [2015](#mol212056-bib-0014){ref-type="ref"}) between *Nco*I and *Eco*RI sites, yielding the final construct DT390‐scFv (FMC63) in pwPICZalpha. To construct DT390‐BiscFv (FMC63), the first scFv (FMC63) was amplified using PCR primers FMC‐Nco carrying *Xho*I and *Nco*I sites + FMC‐Bam1 carrying *Bam*HI and *Eco*RI sites and then cloned into pwPICZalpha between *Xho*I and *Eco*RI sites for sequencing confirmation. The insert was subsequently cut out with *Nco*I + *Bam*HI as insert I. The second scFv (FMC63) was PCR‐amplified using FMC‐Bam2 carrying *Xho*I and *Bam*HI sites + FMC‐Eco carrying an *Eco*RI site and then cloned into pwPICZalpha between *Xho*I and *Eco*RI sites for sequencing confirmation. The insert was then cut out with *Bam*HI + *Eco*RI as insert II. The insert I carrying *Nco*I and *Bam*HI sites + insert II carrying *Bam*HI and *Eco*RI sites \[*Nco*I‐scFv (FMC63)‐*Bam*HI/*Bam*HI‐scFv (FMC63)‐*Eco*RI\] were together cloned into pwPICZalpha‐DT390 between *Nco*I and *Eco*RI, yielding the final construct DT390‐BiscFv (FMC63) in pwPICZalpha. To construct the single‐chain foldback diabody CD19 immunotoxin, it is needed to build a modified scFv (FMC63) with a short linker (one G~4~S) between VL and VH. The VL portion was amplified using PCR primers FMC‐Nco + Bam‐FMC carrying *Bam*HI site and digested using *Bam*HI. The VH portion was amplified using PCR primers BgL‐FMC carrying *Bgl*II site + FMC‐Bam1 and digested using *Bgl* II. The *Bam*HI‐digested VL portion and *Bgl* II‐digested VH were ligated together for 4 h at room temperature as PCR template to amplify the scFv (FMC63) with short linker (one G~4~S) for constructing the single‐chain foldback diabody isoform following the construction procedure for DT390‐BiscFv (FMC63). All PCR primers that were used are listed in Table [2](#mol212056-tbl-0002){ref-type="table-wrap"}.

![Schematic diagrams of the monovalent, bivalent, and single‐chain foldback diabody anti‐human CD19 immunotoxins.](MOL2-11-584-g001){#mol212056-fig-0001}

###### 

PCR primers used in this study

![](MOL2-11-584-g010){#nlm-graphic-5}

John Wiley & Sons, Ltd

CD19 immunotoxin expression in the diphtheria toxin‐resistant yeast *Pichia Pastoris* expression system and purifications were performed as previously described (Peraino *et al*., [2013a](#mol212056-bib-0009){ref-type="ref"}; Wang *et al*., [2011](#mol212056-bib-0012){ref-type="ref"}). Western blot analysis, binding and blocking analysis by flow cytometry were all performed as previously described (Peraino *et al*., [2013a](#mol212056-bib-0009){ref-type="ref"}) using a human CD19^+^ mantle cell lymphoma cell line JeKo‐1. DT390 was used as negative control for *in vitro* functional analysis. C21 immunotoxin (a nonrelated DT390‐based immunotoxin) was used as negative control for *in vivo* efficacy characterization. Both DT390 and C21 immunotoxin were also expressed using yeast *Pichia Pastoris* expression system in our laboratory. Isolation of human PBMC, *in vitro* binding and depletion analysis of the CD19 immunotoxins to human blood, or PBMC with flow cytometry was performed as previously described (Wang *et al*., [2015](#mol212056-bib-0014){ref-type="ref"}).

2.3. *In vitro* efficacy analysis {#mol212056-sec-0005}
---------------------------------

*In vitro* efficacy of the CD19 immunotoxins was assessed using CellTiter‐Glo® Luminescent Cell Viability Assay (Promega, cat\# G7571) to human CD19^+^ mantle cell lymphoma cell line JeKo‐1. Briefly, the JeKo‐1 cells were added to the wells of the opaque‐walled 96‐well plate at 10^4 ^cells/well. The CD19 immunotoxin was diluted in the tissue culture medium and added to the well at final concentration of 10^−6^, 10^−7^, 10^−8^, 10^−9^, 10^−10^, 10^−11^, and 10^−12 ^ [m]{.smallcaps}. The final volume is 100 μL per well for both JeKo‐1 cells and the CD19 immunotoxin. The control wells containing only the tissue culture medium were included to obtain the background luminescence value. Cycloheximide (1.25 mg·mL^−1^) was added to the positive control wells. The plates were incubated for 24 h at 37 °C, 5% CO~2~. The plates were equilibrated at room temperature for approximately 30 min. 100 μL of the CellTiter‐Glo® reagent was added and mixed for 2 min on an orbital shaker to induce cell lysis. The plate was then incubated at room temperature for 10 min to stabilize the luminescent signal, and the luminescence signals were recorded using Wallac Victor2 1420 multilabel counter (Perkin Elmer, Waltham, MA, USA).

2.4. *In vivo* efficacy analysis {#mol212056-sec-0006}
--------------------------------

The breeding pairs of *NSG* mice were purchased from Jackson laboratories (Bar Harbor, Maine) and bred in our rodent barrier facilities. All animal experiments were approved by Massachusetts General Hospital (MGH) Institutional Animal Care and Use Committee (IACUC). The *NSG* mice were divided into following groups: (a) C21 immunotoxin control group (a nonrelated diphtheria toxin‐based immunotoxin as negative control) (*n* = 7); (b) monovalent CD19 immunotoxin group (*n* = 7); (c) bivalent CD19 immunotoxin group (*n* = 7); and (d) single‐chain foldback diabody CD19 immunotoxin group (*n* = 7). All animals were injected IV with 10 million of human CD19^+^ mantle cell lymphoma cells (JeKo‐1) via the tail vein. The immunotoxin was injected IP from day 0 on at 100 μg·kg^−1^, BID for four consecutive days as one course, four courses in total, and three‐day break between any two courses. The injected animals were observed daily for signs and symptoms of illness and scored twice weekly based on the parameters as previously reported by our laboratory (Peraino *et al*., [2013b](#mol212056-bib-0008){ref-type="ref"} and Wang *et al*., [2015](#mol212056-bib-0014){ref-type="ref"}). In addition, to assess whether the CD19 immunotoxin is toxic to the animals, *NSG* mice (*n* = 2) injected with the bivalent CD19 immunotoxin only were also included as control.

2.5. Statistical analysis {#mol212056-sec-0007}
-------------------------

All *p* values were calculated using log‐rank (Mantel--Cox) test of Prism. *p *\<* *0.05 was considered as significant. IC~50~ was determined using nonlinear regression (curve fit) of Prism.

3. Results {#mol212056-sec-0008}
==========

3.1. Expression and purification of the CD19 immunotoxin {#mol212056-sec-0009}
--------------------------------------------------------

As shown in Fig. [1](#mol212056-fig-0001){ref-type="fig"}, monovalent, bivalent, and single‐chain foldback diabody versions of the anti‐human CD19 immunotoxins were constructed to find the isoform with the highest binding affinity and greatest ability to deplete human CD19^+^ cells. The codon‐optimized anti‐human CD19 scFv (FMC63) DNA (Fig. [2](#mol212056-fig-0002){ref-type="fig"}) (Nicholson *et al*., [1997](#mol212056-bib-0006){ref-type="ref"}) was cloned into the C terminus of the DT390‐containing yeast *Pichia Pastoris* expression vector pwPICZalpha‐DT390 between the *Nco*I and *Eco*RI sites (Wang *et al*., [2015](#mol212056-bib-0014){ref-type="ref"}). A 6xHis tag was added to the C terminus of each immunotoxin isoform to facilitate the purification. The DT390 domain was genetically linked to the scFv (FMC63) domain by a linker containing four glycine residues and a serine residue (G~4~S). For the monovalent and bivalent versions, the VL and VH were linked together by a long linker (G~4~S)~3~ to generate the scFv (FMC63). For the single‐chain foldback diabody isoform, the VL and VH were linked by a short linker G~4~S. The two scFv (FMC63) of the bivalent and the single‐chain foldback diabody isoforms were also joined by a long linker (G~4~S)~3~.

![Codon‐optimized anti‐human CD19 scFv (FMC63) DNA and amino acid sequence.](MOL2-11-584-g002){#mol212056-fig-0002}

The CD19 immunotoxins were expressed using unique diphtheria toxin‐resistant yeast *Pichia Pastoris* (Liu *et al*., [2003](#mol212056-bib-0004){ref-type="ref"}) expression system in 1‐L Erlenmeyer flasks. The CD19 immunotoxins were captured using a Ni‐Sepharose fast flow resin and further purified using strong anion‐exchange resin. The final purification yield was \~ 15 mg per liter for the monovalent and \~ 6 mg per liter for the bivalent and \~ 2 mg per liter for the single‐chain foldback diabody CD19 immunotoxins of the original harvested supernatant. The purified anti‐human CD19 immunotoxins were analyzed by SDS/PAGE (Fig. [3](#mol212056-fig-0003){ref-type="fig"}A) and western blot using a mouse anti‐6xHis mAb (Fig. [3](#mol212056-fig-0003){ref-type="fig"}B) and a mouse antidiphtheria toxin mAb (Fig. [3](#mol212056-fig-0003){ref-type="fig"}C). SDS/PAGE and western blot analysis demonstrated that the three versions of the CD19 immunotoxins were expressed and purified with expected molecular weight of 70.09 kDa for the monovalent isoform, 96.95 kDa for the bivalent isoform, and 95.69 kDa for the single‐chain foldback diabody isoform.

![SDS/PAGE, western blot analysis of the anti‐human CD19 immunotoxins. (A) SDS/PAGE analysis (4--12% NuPAGE, Thermo Fisher Scientific); (B) western blot analysis using a mouse anti‐His mAb (clone\#: 4A12E4, Thermo Fisher Scientific); (C) western blot analysis using a mouse antidiphtheria toxin mAb (clone\# 3B6, Meridian). Lane 1: protein marker; Lanes 2--3: monovalent anti‐human CD19 immunotoxin \[DT390‐scFv (FMC63), 70.09 kDa\]; Lanes 4--5: bivalent anti‐human CD19 immunotoxin \[DT390‐BiscFv (FMC63), 96.95 kDa\]; Lanes 6--7: single‐chain foldback diabody anti‐human CD19 immunotoxin (95.69 kDa).](MOL2-11-584-g003){#mol212056-fig-0003}

3.2. Binding affinity analysis of the CD19 immunotoxins using flow cytometry {#mol212056-sec-0010}
----------------------------------------------------------------------------

CD19 immunotoxins were designed to deplete human CD19^+^ cells via binding of the anti‐human CD19 scFv (FMC63) domain of the immunotoxins on the CD19 receptor of the CD19^+^ cells. Following the internalization, the released DT390 domain functions to inhibit protein synthesis resulting in the cell death (Murphy, [2011](#mol212056-bib-0005){ref-type="ref"}); therefore, the first step to characterize the CD19 immunotoxins was to analyze their binding affinity to human CD19 receptor. The anti‐human CD19 immunotoxins were biotin‐labeled for the binding analysis to human CD19^+^ JeKo‐1 cells using flow cytometry. As shown in Fig. [4](#mol212056-fig-0004){ref-type="fig"}A, monovalent (left panel), bivalent (middle panel), and single‐chain foldback diabody (right panel) CD19 immunotoxins bound to the human CD19 in a dose‐dependent manner. The binding affinity was quantified by the dissociation constant (*K* ~*D*~) for each CD19 immunotoxin isoform using mean fluorescence intensity (MFI) (Peraino *et al*., [2013a](#mol212056-bib-0009){ref-type="ref"}). The foldback diabody isoform (*K* ~D~ * *= 11.22 n[m]{.smallcaps}, Fig. [4](#mol212056-fig-0004){ref-type="fig"}D) bound stronger than the monovalent isoform (*K* ~D~ = 47.42 n[m]{.smallcaps}, Fig. [4](#mol212056-fig-0004){ref-type="fig"}B). However, the bivalent isoform exhibited the highest binding affinity (*K* ~D~ = 4.59 n[m]{.smallcaps}, Fig. [4](#mol212056-fig-0004){ref-type="fig"}C).

![(A) Flow cytometry binding analysis of biotinylated monovalent anti‐human CD19 immunotoxin \[DT390‐scFv (FMC63)\] (left panel), bivalent anti‐human CD19 immunotoxin \[DT390‐BiscFv (FMC63)\] (middle panel), single‐chain foldback diabody anti‐human CD19 immunotoxin (right panel) to human CD19^+^ JeKo‐1 cells (mantle cell lymphoma cell line). Cells incubated with only the secondary staining (PE‐conjugated streptavidin) served as a negative control and PE‐mouse anti‐human CD19 mAb (clone\#HIB19, BioLegend, cat\#302208) for the positive control. PE‐mouse anti‐human CD194 (CCR4) (clone\#L291H4, BioLegend, cat\#359412) served as isotype control. Biotin‐labeled porcine CD3‐εγ (Peraino *et al*., [2012](#mol212056-bib-0007){ref-type="ref"}) was included as a negative control for background due to protein biotinylation. The data are representative of three individual experiments. (B‐D) *K*~D~ determination using flow cytometry and nonlinear least‐squares fit. MFI was plotted over a wide range of concentrations of biotinylated (B) DT390‐scFv (FMC63), (C) DT390‐BiscFv (FMC63), and (D) single‐chain foldback diabody anti‐human CD19 immunotoxin. The accompanying least‐squares fits are shown based on the hyperbolic equation y = m1 + m2 \* m0/(m3 + m0), where y = MFI at the given biotinylated anti‐human CD19 immunotoxin concentration; m0 = biotinylated anti‐human CD19 immunotoxin concentration; m1 = MFI of zero biotinylated anti‐human CD19 immunotoxin control; m2 = MFI at saturation; and m3 = *K*~D~. A fitted *K*~D~ of 47.4 n[m]{.smallcaps} was obtained for DT390‐scFv (FMC63), 4.59 n[m]{.smallcaps} for DT390‐BiscFv (FMC63), and 11.2 n[m]{.smallcaps} for single‐chain foldback diabody anti‐human CD19 immunotoxin.](MOL2-11-584-g004){#mol212056-fig-0004}

The binding specificity of the CD19 immunotoxins was further analyzed by blocking the binding of the parent anti‐human CD19 mAb (FMC63) to its receptor on human CD19^+^ JeKo‐1 tumor cells. As shown in Fig. [5](#mol212056-fig-0005){ref-type="fig"}, monovalent (left panel), bivalent (middle panel), and single‐chain foldback diabody (right panel) CD19 immunotoxins blocked the binding of anti‐human CD19 mAb (FMC63) to the JeKo‐1 cells in a dose‐dependent fashion. The data strongly suggest that the CD19 immunotoxins bind specifically to the human CD19 receptor.

![Blocking analysis of the anti‐human CD19 immunotoxins for the human CD19 receptor on human CD19^+^ JeKo‐1 lymphoma cells. Unlabeled anti‐human CD19 immunotoxins were each incubated with JeKo‐1 cells at a range of concentrations for 15 min at 4 °C in the dark. Subsequently, without washing the cells, anti‐human CD19 mAb (FMC63) was added to each tube containing cells in the presence of the unlabeled immunotoxins. Binding affinity of the anti‐human CD19 immunotoxins to the human CD19 receptor on JeKo‐1 cells was measured by a decrease in anti‐human CD19 mAb staining in the presence of increasing concentrations of the unlabeled immunotoxins.](MOL2-11-584-g005){#mol212056-fig-0005}

3.3. *In vitro* efficacy analysis of the CD19 immunotoxin {#mol212056-sec-0011}
---------------------------------------------------------

*In vitro* efficacy of the CD19 immunotoxins was assessed using CellTiter‐Glo® Luminescent Cell Viability Assay (Promega) in a human CD19^+^ JeKo‐1 tumor cell line. As shown in Fig. [6](#mol212056-fig-0006){ref-type="fig"}, all of the three CD19 immunotoxin isoforms (monovalent, bivalent, and foldback diabody) were effective. The foldback diabody isoform (IC~50~ = 1.7 × 10^−11 ^ [m]{.smallcaps}) was better than the monovalent isoform (IC~50~ = 2 × 10^−10 ^ [m]{.smallcaps}), while the bivalent isoform (IC~50~ = 2 × 10^−12 ^ [m]{.smallcaps}) was greatest. This findings correlate well with the corresponding binding affinity analysis.

![*In vitro* efficacy analysis of the CD19 immunotoxins using CellTiter‐Glo® Luminescent Cell Viability Assay (Promega, cat\# G7571) to human CD19^+^ mantle cell lymphoma cell line JeKo‐1. (a) Monovalent anti‐human CD19 immunotoxin \[DT390‐scFv (FMC63), green line\]; (b) bivalent anti‐human CD19 immunotoxin \[DT390‐BiscFv (FMC63), red line\]; (c) single‐chain foldback diabody anti‐human CD19 immunotoxin (blue line); (d) DT390 alone (purple line). Y‐axis: inhibition rate of the cell viability by determining the number of viable cells based on the quantification of the ATP present. X‐axis: plated anti‐human CD19 immunotoxin concentration. Cycloheximide (1.25 mg·mL^−1^) was used as a positive control. The negative control contained cells without immunotoxin. *p *\<* *0.0001 by log‐rank (Mantel--Cox) test of Prism (*n* = 3). Error bars indicate ±SD. Data are representative of multiple assays.](MOL2-11-584-g006){#mol212056-fig-0006}

3.4. *In vitro* binding and depletion analysis of the CD19 immunotoxins to human blood or PBMC {#mol212056-sec-0012}
----------------------------------------------------------------------------------------------

CD19 is expressed on normal human B cells. To further characterize the CD19 immunotoxins, we performed *in vitro* binding and depletion analyses of the CD19 immunotoxins in human blood or PBMC. As shown in Fig. [7](#mol212056-fig-0007){ref-type="fig"}A, all three isoforms of the biotinylated CD19 immunotoxins bound to CD19^+^ human blood in a dose‐dependent fashion. The foldback diabody isoform bound more strongly than the monovalent isoform, while the bivalent isoform was best, which is consistent with the previous binding analysis using the human CD19^+^ JeKo‐1 cell line. We then further performed *in vitro* depletion analysis in CD19^+^ human PBMC using the CD19 immunotoxins. As shown in Fig. [7](#mol212056-fig-0007){ref-type="fig"}B, CD19^+^ human PBMC was depleted in a dose‐dependent manner following incubation of the CD19 immunotoxin with the human PBMC for 48 h. The bivalent and foldback diabody isoforms were better than the monovalent isoform, while the bivalent isoform was the most effective.

![*In vitro* binding and depletion analysis of the anti‐human CD19 immunotoxins to human CD19^+^ blood or PBMC. (A) Flow cytometry binding analysis of the anti‐human CD19 immunotoxins to the CD19^+^ cells within human blood. Monovalent: monovalent anti‐human CD19 immunotoxin \[DT390‐scFv (FMC63)\]; bivalent: bivalent anti‐human CD19 immunotoxin \[DT390‐BiscFv (FMC63)\]; foldback: single‐chain foldback diabody anti‐human CD19 immunotoxin. PE‐SA:PE‐conjugated streptavidin; bio‐pCD3εγ: biotin‐labeled porcine CD3εγ (Peraino *et al*., [2012](#mol212056-bib-0007){ref-type="ref"}). (B) *In vitro* depletion of the CD19^+^ cells within human PBMC using the anti‐human CD19 immunotoxins. C21 immunotoxin and DT390 alone were included as negative controls. Data of both (A) and (B) are representative of three individual experiments.](MOL2-11-584-g007){#mol212056-fig-0007}

3.5. Off‐target analysis of the CD19 immunotoxin {#mol212056-sec-0013}
------------------------------------------------

To rule out the off‐target effect of the CD19 immunotoxin, three human CD19^−^ tumor cell lines were analyzed with biotinylated bivalent human CD19 immunotoxin using flow cytometry: (a) CCRF‐CEM, (b) M14, and (c) MD‐MBA‐231. The results demonstrated that there was no binding activity with the three human CD19^−^ tumor cell lines (Fig. [8](#mol212056-fig-0008){ref-type="fig"}A). The viability of the three human CD19^−^ tumor cell lines was also analyzed by flow cytometry using 7‐aminoactinomycin D and Annexin V staining following incubation with the bivalent CD19 immunotoxin for 18 h. Their viability was not affected by this treatment (Fig. [8](#mol212056-fig-0008){ref-type="fig"}B).

![Off‐target analysis of the CD19 immunotoxin. (A) Flow cytometry binding analysis of the biotinylated bivalent anti‐human CD19 immunotoxin to three human CD19^−^ tumor cells (CCRF‐CEM, M14, and MD‐MBA‐231). PE‐mouse anti‐human CD19 mAb was included as positive antibody control, and biotinylated porcine CD3‐εγ (Peraino *et al*., [2012](#mol212056-bib-0007){ref-type="ref"}) as a negative control for background due to protein biotinylation. (B) Cell viability analysis of the three human CD19^−^ tumor cell lines by staining with 7‐ADD and Annexin V following incubation with the bivalent anti‐human CD19 immunotoxin for 18 h. (C) Depletion analysis by flow cytometry for the human CD19^−^ subpopulations within human PBMC following incubation with the bivalent anti‐human CD19 immunotoxin for 48 h. The data are representative of three individual experiments for all of the data in figure.](MOL2-11-584-g008){#mol212056-fig-0008}

To further rule out the off‐target effect of the CD19 immunotoxin, we also analyzed the human CD19^−^ PBMC populations following incubation with the bivalent CD19 immunotoxin for 48 h: CD4 T cell (CD3^+^CD4^+^), CD8 T cell (CD3^+^CD8^+^), NK cells (CD16^+^CD8^+^), and monocyte (CD14^+^CD16^+^). The results demonstrated that there was no effect on human CD19^−^ PBMC populations (Fig. [8](#mol212056-fig-0008){ref-type="fig"}C).

3.6. *In vivo* efficacy analysis of the CD19 immunotoxins {#mol212056-sec-0014}
---------------------------------------------------------

*In vivo* efficacy of the CD19 immunotoxins was assessed using human CD19^+^ JeKo‐1 mantle cell lymphoma‐bearing immunodeficient *NSG* mouse model. Human CD19^+^ JeKo‐1 cells (1 × 10^7^) were injected IV and the CD19 immunotoxins were injected IP at 100 μg·kg^−1^, BID, for four consecutive days as one course, four courses in total, and three‐day break between any two courses. As shown in Fig. [9](#mol212056-fig-0009){ref-type="fig"}, the C21 immunotoxin was included as a negative control (*n* = 7). These data demonstrated that all three CD19 immunotoxin isoforms prolonged animal survival significantly from a median of 31 days in the negative control group (C21 immunotoxin) to 34 days in the monovalent isoform treatment group (*n* = 7, *p *\<* *0.0001), to 36 days in the foldback diabody isoform treatment group (*n* = 7, *p *\<* *0.0001), to 40 days in the bivalent isoform treatment group (*n* = 7, *p *\<* *0.0001) (Fig. [9](#mol212056-fig-0009){ref-type="fig"}). Mice receiving the CD19 immunotoxin only did not show any toxicity (data not shown). All animals injected with the human CD19^+^ JeKo‐1 cells succumbed to tumors (data not shown).

![*In vivo* efficacy analysis of the anti‐human CD19 immunotoxins. *NSG* mice were injected IV with 1.0 × 10^7^ human CD19^+^ JeKo‐1 lymphoma cells and treated from day 0 on with the anti‐human CD19 immunotoxin (IP injection) at 100 μg·kg^−1^ BID for four consecutive days as one course, four courses in total, and three‐day break between any two courses. (a) C21 immunotoxin control group (a nonrelated DT390‐based immunotoxin as negative control) (*n* = 7, green curve) with a median survival time of 31 days; (b) monovalent anti‐human CD19 immunotoxin group (*n* = 7, blue curve) with a median survival time of 34 days; (c) bivalent anti‐human CD19 immunotoxin group (*n* = 7, red curve) with a median survival time of 40 days; (d) single‐chain foldback diabody anti‐human CD19 immunotoxin group (*n* = 7, purple curve) with a median survival time of 36 days. The schedule of drug and tumor cell injection is pictured in the schematic below the survival curve. The vertical arrows indicate the days on which the tumor cells or anti‐human CD19 immunotoxins were injected.](MOL2-11-584-g009){#mol212056-fig-0009}

4. Discussion {#mol212056-sec-0015}
=============

Several attempts to develop recombinant anti‐human CD19 immunotoxins have been unsuccessful (Du *et al*., [2008](#mol212056-bib-0002){ref-type="ref"}). We speculate that the use of an inappropriate expression system was part of the problem. Diphtheria toxin‐resistant yeast *Pichia Pastoris* expression system is suitable for DT390‐based immunotoxin development. We speculate that eukaryotic expression systems such as yeast *Pichia Pastoris* expression system might be better than prokaryotic expression system such as *E. coli*.

Based on our previous experience, the foldback diabody immunotoxin isoform is superior to both bivalent and monovalent isoforms in terms of the *in vitro* binding affinity and efficacy (Kim *et al*., [2007](#mol212056-bib-0003){ref-type="ref"}; Wang *et al*., [2015](#mol212056-bib-0014){ref-type="ref"}). However, the foldback diabody isoform in this study did not improve the *in vitro* binding affinity and efficacy comparing with the bivalent isoform. Therefore, it is case by case for the immunotoxin development to find the best isoform (Wei *et al*., [2014](#mol212056-bib-0016){ref-type="ref"}).

The *in vivo* dosing schedule (Fig. [9](#mol212056-fig-0009){ref-type="fig"}) in this study has not been optimized. Our focus was simply to assess whether the CD19 immunotoxin functions *in vivo*. There is still room to increase the dose and duration to improve the animal survival. It is also necessary to characterize the *in vivo* efficacy further using established xenograft tumor‐bearing *NSG* mouse model. Furthermore, analyzing the residue tumor cells *in vitro* to determine whether they are still sensitive to the CD19 immunotoxin is warranted. If they remain sensitive, higher doses and multiple course of treatment could improve animal survival further.

Conventional chemotherapy and targeted mAb therapy have contributed significantly to the treatment for CD19^+^ B‐cell leukemia/lymphoma. However, there is still an unmet need to develop novel targeted therapies against the relapsing/refractory patients with CD19^+^ leukemia/lymphoma following the chemotherapy and targeted mAb therapy. We believe that CD19 immunotoxin will provide a novel alternative therapy for the refractory/relapsing CD19^+^ tumor patients.
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